Evidence map›Paper›PMID 23931426›Full record

ArticleAcademic radiology2013

Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.

Fernando Arias-Mendoza, Geoffrey S Payne, Kristen Zakian, Marion Stubbs, Owen A O'Connor, Hamed Mojahed, Mitchell R Smith, Adam J Schwarz, Amita Shukla-Dave, Franklyn Howe and 11 more

Abstract read
In one paragraph

Article in Academic radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. MRI-only treatment planning: benefits and challenges.Physics in medicine and biology · 2018
    Review
  4. Article
  5. Review
  6. Radiotherapy planning using MRI.Physics in medicine and biology · 2015
    Article
  7. Functional MRI and CT biomarkers in oncology.European journal of nuclear medicine and molecular imaging · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 3 countries.

Fernando Arias-MendozaDepartment of Radiology, Columbia University, 710 W 168th St., Neurological Institute Basement, Room B-057, New York, NY 10032, USA. fa2003@columbia.edu
Geoffrey S Payne
Kristen Zakian
Marion Stubbs
Owen A O'Connor
Hamed Mojahed
Mitchell R Smith
Adam J Schwarz
Amita Shukla-Dave
Franklyn Howe
Harish Poptani
Seung-Cheol Lee
Ruth Pettengel
Steven J Schuster
David Cunningham
Arend Heerschap
Jerry D Glickson
John R Griffiths
Jason A Koutcher
Martin O Leach
Truman R Brown
University of Pennsylvania · USMemorial Sloan Kettering Cancer Center · USCancer Research UK Cambridge Center · GBInstitute of Cancer Research · GBRoyal Marsden Hospital · GBSt George's Hospital · GBThe Neurological Institute · USColumbia University · USColumbia University Irving Medical Center · USFox Chase Cancer Center · USRadboud University Medical Center · NL

Funding

IN VIVO 31P MRS STUDIES OF NON-HODGKIN'S LYMPHOMAR01CA118559 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ARIAS-MENDOZA, FERNANDO · 2007 to 2010
$5.0M
PREDICTING OUTCOME OF EXPERIMENTAL THERAPY IN LYMPHOMAS BY 31P & 1H MRSR21CA152858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ARIAS-MENDOZA, FERNANDO · 2010 to 2011
$355k
Cancer Research UK 11562Cancer Research UK 16464Medical Research Council G0701533NCI NIH HHS R01 CA118559NCI NIH HHS R21 CA152858
6 · The paper itself

Abstract

RATIONALE AND

objectivesBased on their association with malignant proliferation, using noninvasive phosphorus MR spectroscopic imaging ((31)P MRSI), we measured the tumor content of the phospholipid-related phosphomonoesters (PME), phosphoethanolamine and phospholcholine, and its correlation with treatment outcome in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) receiving standard first-line chemotherapy. EXPERIMENTAL

designThe PME value normalized to nucleoside triphosphates (PME/NTP) was measured using (31)P MRSI in tumor masses of 20 patients with DLBCL before receiving standard first-line chemotherapy. Response at 6 months was complete in 13 patients and partial in seven. Time to treatment failure (TTF) was ≤11 months in eight patients, from 18 to 30 months in three, and ≥60 months in nine.

resultsOn a t test, the pretreatment tumor PME/NTP mean value (SD, n) of patients with a complete response at 6 months was 1.42 (0.41, 13), which was significantly different from the value of 2.46 (0.40, 7) in patients with partial response (P < .00001). A Fisher test significantly correlated the PME/NTP values with response at 6 months (sensitivity and specificity at 0.85, P < .004) while a Cox proportional hazards regression significantly correlated the PME/NTP values with TTF (hazard ratio = 5.21, P < .02). A Kaplan-Meier test set apart a group entirely composed of patients with TTF ≤ 11 months (hazard ratio = 8.66, P < .00001).

conclusionsThe pretreatment tumor PME/NTP values correlated with response to treatment at 6 months and time to treatment failure in newly diagnosed patients with DLBCL treated with first-line chemotherapy, and therefore they could be used to predict treatment outcome in these patients.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCyclophosphamideDoxorubicinFemaleHumansLymphoma, B-CellMagnetic Resonance SpectroscopyMaleMiddle AgedPhospholipidsPhosphorus IsotopesPrednisoneBiomarkers, TumorCyclophosphamideDoxorubicinPhospholipidsPhosphorus IsotopesPrednisoneVincristineIn vivolymphomametabolic imagingMR spectroscopyprediction of therapy outcome

Identifiers

PMID23931426
PMCPMC3810177
OpenAlexW2094499484

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.